Swiss Atrial Fibrillation Cohort Study (SWISS-AF)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02105844 |
Recruitment Status :
Active, not recruiting
First Posted : April 7, 2014
Last Update Posted : May 24, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Swiss-AF is a prospective observational, multicentric cohort study in Switzerland. Overall, 2600 patients with documented atrial fibrillation aged >65 years will be included and followed on a yearly basis.
Yearly clinical examinations include a detailed questionnaire on personal characteristics, a resting electrocardiogram, neurocognitive function tests and questionnaires on disability and quality of life. Blood sampling and brain magnetic resonance imaging are scheduled at baseline and after 2 years of follow-up.
The main study aims of this long term prospective study are to increase our knowledge on structural brain damage and its changes over time in patients with atrial fibrillation, to gain additional insights on the incidence and underlying mechanisms of cognitive decline in patients with atrial fibrillation and to evaluate the interrelationships of structural and functional brain damage in this population.
Condition or disease |
---|
Atrial Fibrillation |
Study Type : | Observational |
Actual Enrollment : | 2415 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Swiss Atrial Fibrillation Cohort Study - SWISS AF |
Actual Study Start Date : | March 2014 |
Estimated Primary Completion Date : | March 2030 |
Estimated Study Completion Date : | March 2030 |

Group/Cohort |
---|
Atrial Fibrillation
Cohort Study on patients with atrial fibrillation in Switzerland
|
- Stroke or systemic embolism [ Time Frame: 2018 (after an average of 2.5 years of follow-up) ]
- Hospitalization for heart failure [ Time Frame: 2018 (after an average of 2.5 years of follow-up) ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- atrial fibrillation documented within the last 24 months
- age >=45 years
Exclusion Criteria:
- acute illness
- inability to provide informed consent
- Only short episodes of reversible forms of atrial fibrillation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02105844
Switzerland | |
University Hospital | |
Basel, Basel-Stadt, Switzerland, 4031 |
Study Director: | Stefan Osswald, MD, Prof. | University Hospital, Basel, Switzerland | |
Principal Investigator: | Michael Kuehne, MD, PD, exec. MBA | University Hospital, Basel, Switzerland | |
Principal Investigator: | David Conen, MD MPH | McMaster University, Population Health Research Institute, Hamilton, Canada |
Responsible Party: | University Hospital, Basel, Switzerland |
ClinicalTrials.gov Identifier: | NCT02105844 |
Other Study ID Numbers: |
SWISS-AF |
First Posted: | April 7, 2014 Key Record Dates |
Last Update Posted: | May 24, 2022 |
Last Verified: | May 2022 |
atrial fibrillation dementia cognitive dysfunction stroke Magnetic resonance imaging |
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |